Selected Posters and Abstracts
Darunavir (Prezista) [PI]
[P196] Phenotypic and genotypic determinants of TMC114 (darunavir) resistance: POWER 1, 2 and 3 pooled analysis 11/27/06
[P295] Pharmacokinetic interaction between TMC114, a new protease inhibitor, and the selective serotonin reuptake inhibitors, paroxetine and sertraline 11/27/06
[PL5.1] Use of TMC114 in combination with other drugs: guidance from pharmacokinetic studies 11/27/06
[P28] TMC114/r has tolerability and efficacy benefits for treatment-experienced patients compared with control PIs: overview of the POWER trials 11/27/06
[P217] Kinetic characterisation of protease inhibitor binding to HIV-1 variants with decreased TMC114 susceptibility 11/27/06
[P294] Pharmacokinetic interaction between TMC114, a new protease inhibitor, and methadone 11/27/06
[P51] Cost-effectiveness of TMC114 (darunavir)/ritonavir compared with currently available protease inhibitors in treatment-experienced HIV patients 11/27/06
[P29] TMC114/r provides greater efficacy benefits versus control protease inhibitor(s), regardless of the protease inhibitor or sensitivity to the protease inhibitor: POWER 1 and 2 trials  11/27/06
[P371] Salvage therapy in perinatally acquired HIV infection: first UK experience of TMC114  11/27/06
[P360] Emerging multi-drug resistance in children with perinatally acquired HIV-1 11/27/06

 

<— Conference Main Page

Conference
Main Page


FDA-Approved
HIV and AIDS Treatments

Protease Inhibitors
Agenerase
Aptivus
Crixivan
Fortovase
Invirase
Kaletra
Lexiva

Norvir
Prezista

Reyataz
Viracept


Nucleoside / Nucleotide Reverse Transcriptase Inhibitors

Combivir
Epivir
Emtriva
Epzicom
Hivid
Retrovir
Trizivir
Truvada  
Videx
Viread
Zerit
Ziagen


non Nucleoside Reverse Transcriptase Inhibitors
Rescriptor

Sustiva
Viramune

Entry Inhibitors
Fuzeon

Fixed-dose Combinations
Atripla
Combivir
Trizivir
Truvada